Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
- PMID: 23326187
- PMCID: PMC3544267
- DOI: 10.2147/BTT.S30133
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
Abstract
Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues. Reslizumab (Cinquil™) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. This review will consider the current status of the clinical development of reslizumab for asthma and in other inflammatory diseases with a marked eosinophilic component.
Keywords: IL-5; asthma; eosinophil.
Similar articles
-
Reslizumab for pediatric eosinophilic esophagitis.Immunotherapy. 2010 Jul;2(4):461-5. doi: 10.2217/imt.10.41. Immunotherapy. 2010. PMID: 20636000
-
Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions.Curr Opin Mol Ther. 2009 Jun;11(3):329-36. Curr Opin Mol Ther. 2009. PMID: 19479666
-
Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.Expert Opin Drug Metab Toxicol. 2018 Feb;14(2):239-245. doi: 10.1080/17425255.2018.1421170. Epub 2017 Dec 27. Expert Opin Drug Metab Toxicol. 2018. PMID: 29268638 Review.
-
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?Front Immunol. 2017 Mar 10;8:242. doi: 10.3389/fimmu.2017.00242. eCollection 2017. Front Immunol. 2017. PMID: 28344579 Free PMC article. Review.
-
Reslizumab in the management of poorly controlled asthma: the data so far.J Asthma Allergy. 2016 Aug 31;9:155-62. doi: 10.2147/JAA.S94164. eCollection 2016. J Asthma Allergy. 2016. PMID: 27621657 Free PMC article. Review.
Cited by
-
Reslizumab as add-on therapy in patients with refractory asthma.BMJ Open Respir Res. 2020 Apr;7(1):e000494. doi: 10.1136/bmjresp-2019-000494. BMJ Open Respir Res. 2020. PMID: 32273395 Free PMC article. Clinical Trial. No abstract available.
-
Update on reslizumab for eosinophilic asthma.Expert Opin Biol Ther. 2015;15(10):1531-9. doi: 10.1517/14712598.2015.1090972. Expert Opin Biol Ther. 2015. PMID: 26372797 Free PMC article. Review.
-
Role of biologics in severe eosinophilic asthma - focus on reslizumab.Ther Clin Risk Manag. 2016 Jul 1;12:1075-82. doi: 10.2147/TCRM.S111862. eCollection 2016. Ther Clin Risk Manag. 2016. PMID: 27445482 Free PMC article. Review.
-
CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors.MAbs. 2016;8(3):436-53. doi: 10.1080/19420862.2015.1119352. Epub 2015 Dec 14. MAbs. 2016. PMID: 26651396 Free PMC article.
-
Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.Int J Mol Sci. 2025 Feb 18;26(4):1729. doi: 10.3390/ijms26041729. Int J Mol Sci. 2025. PMID: 40004192 Free PMC article. Review.
References
-
- Walsh GM. Antagonism of eosinophil accumulation in asthma. Recent Pat Inflamm Allergy Drug Discov. 2010;4(3):210–213. - PubMed
-
- Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323(15):1033–1039. - PubMed
-
- Nissim Ben Efraim AH, Levi-Schaffer F. Tissue remodeling and angiogenesis in asthma: the role of the eosinophil. Ther Adv Respir Dis. 2008;2(3):163–171. - PubMed
-
- Walsh GM. Advances in the immunobiology of eosinophils and their role in disease. Crit Rev Clin Lab Sci. 1999;36(5):453–496. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources